Revelation Biosciences, Inc.
$1.06 $0.00 (+0.00%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jun 17
The stock moved +11.3% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jun 17 -
May 8
From its Jan 30 high, the share price fell 53%.
Peak close $2.03 on Jan 30; trough close $0.96 on May 8. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -53% -
Feb 6
The stock moved +12.2% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 6
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Revelation Biosciences, Inc.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.